Korro Bio, Inc. (NASDAQ:KRRO) CFO Vineet Agarwal Sells 800 Shares

Korro Bio, Inc. (NASDAQ:KRROGet Free Report) CFO Vineet Agarwal sold 800 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $70.00, for a total transaction of $56,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Vineet Agarwal also recently made the following trade(s):

  • On Thursday, October 17th, Vineet Agarwal sold 10,216 shares of Korro Bio stock. The shares were sold at an average price of $78.26, for a total value of $799,504.16.

Korro Bio Price Performance

KRRO opened at $49.70 on Friday. The business’s 50-day moving average price is $49.77 and its two-hundred day moving average price is $46.92. Korro Bio, Inc. has a 1 year low of $30.00 and a 1 year high of $98.00.

Korro Bio (NASDAQ:KRROGet Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($2.26) EPS for the quarter, topping the consensus estimate of ($2.55) by $0.29. Equities analysts anticipate that Korro Bio, Inc. will post -10.02 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Brown Brothers Harriman & Co. bought a new position in shares of Korro Bio in the second quarter valued at about $28,000. Quest Partners LLC grew its stake in Korro Bio by 172.1% in the 3rd quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock valued at $59,000 after buying an additional 1,124 shares during the last quarter. MetLife Investment Management LLC raised its holdings in Korro Bio by 129.0% in the 3rd quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock valued at $122,000 after acquiring an additional 2,050 shares during the period. Lynx1 Capital Management LP acquired a new stake in Korro Bio during the second quarter worth approximately $129,000. Finally, BNP Paribas Financial Markets boosted its stake in Korro Bio by 1,018.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company’s stock valued at $164,000 after purchasing an additional 4,470 shares during the period. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on KRRO shares. Raymond James began coverage on Korro Bio in a research report on Monday, October 21st. They issued a “strong-buy” rating and a $153.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $115.00 price target on shares of Korro Bio in a research report on Wednesday. William Blair restated an “outperform” rating on shares of Korro Bio in a research report on Wednesday. Finally, Royal Bank of Canada boosted their target price on shares of Korro Bio from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Monday, October 21st. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $142.17.

Read Our Latest Research Report on KRRO

About Korro Bio

(Get Free Report)

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Featured Articles

Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.